{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:14:46Z","timestamp":1793650486461,"version":"4.5.1"},"reference-count":21,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Janus kinase (JAK) inhibitors have expanded the therapeutic options for moderate-to-severe atopic dermatitis (AD). The possibility of dose modulation with abrocitinib (100 and 200 mg) and upadacitinib (15 and 30 mg), both selective JAK1 inhibitors, represents a potential clinical advantage, allowing dose escalation in cases of insufficient response and dose de-escalation in the setting of poor tolerability or during maintenance treatment. However, real-world data remain limited, and the rationale for dose adjustment is not always standardized. This study aimed to describe, using a real-world database, the frequency, timing, and reasons for dose modifications of these agents. Materials and Methods: We retrospectively analyzed the clinical data of 212 patients with moderate-to-severe AD treated with abrocitinib (n = 47) or upadacitinib (n = 165). Dose adjustments, including dose escalation and dose de-escalation, were recorded together with their timing and clinical reasons. Results: In the abrocitinib group, 34\/47 patients (72.3%) initiated treatment at 100 mg, whereas 13\/47 patients (27.7%) started at 200 mg. Six patients (12.8%) underwent a dose adjustment. One patient (2.1%) switched from 200 to 100 mg because of complete AD remission and concomitant menstrual cycle alterations, whereas five patients (10.6%) underwent dose escalation from 100 to 200 mg because of incomplete disease control. Among the six abrocitinib-treated patients who underwent dose adjustment, achievement of IGA 0\/1 after dose modification was documented in all cases. In the upadacitinib group, 93\/165 patients (56.4%) started at 15 mg, whereas 72\/165 patients (43.6%) started at 30 mg. Overall, 44\/165 patients (26.7%) underwent at least one dose adjustment, accounting for a total of 50 dose modifications: 27 escalations from 15 to 30 mg and 23 de-escalations from 30 to 15 mg. Among patients initiating treatment at 15 mg, 23\/93 patients (24.7%) increased the dose to 30 mg after a median of 33.1 weeks because of suboptimal disease control. Among those starting at 30 mg, 21\/72 patients (29.2%) reduced the dose to 15 mg after a median of 44.3 weeks. Of these, 12\/21 patients (57.1%) reduced the dose because of adverse events, including herpetic infections and acne, whereas the remaining patients de-escalated because of optimal disease control. Some patients underwent multiple dose modifications: four followed a 30\u219215\u219230 mg sequence, with re-escalation after 13.2 weeks because of suboptimal disease control, and two followed a 15\u219230\u219215 mg sequence, with dose reduction after approximately 26.7 weeks because of herpes zoster. Overall, 29\/44 patients achieved IGA 0\/1 within 16 weeks and 38\/44 within 32 weeks after dose modification. Conclusions: In this real-world cohort, dose adjustments of selective JAK1 inhibitors were frequently performed in patients with moderate-to-severe AD, particularly among those treated with upadacitinib. Dose escalation was mainly used to address suboptimal disease control, whereas dose de-escalation was performed in the setting of adverse events or optimal disease control. The availability of two dosing regimens may allow treatment intensity to be adapted to individual disease severity, response, and tolerability, supporting a personalized approach to AD management.<\/jats:p>","DOI":"10.3390\/medicina62061127","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:58:12Z","timestamp":1781053092000},"page":"1127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dose Adjustment of JAK Inhibitors for the Management of Moderate-to-Severe Atopic Dermatitis: A Single-Centre Retrospective Study"],"prefix":"10.3390","volume":"62","author":[{"given":"Costanza","family":"Falcidia","sequence":"first","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3446-6648","authenticated-orcid":false,"given":"Francesco","family":"D\u2019Oria","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0527-706X","authenticated-orcid":false,"given":"Giulio","family":"Foggi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5171-9854","authenticated-orcid":false,"given":"Paola","family":"Facheris","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Dermatology Unit, Sant\u2019Anna Hospital, ASST-Lariana, 22100 Como, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9859-4475","authenticated-orcid":false,"given":"Matteo","family":"Bianco","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-4866","authenticated-orcid":false,"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/jdv.17272","article-title":"Topical Therapy of Atopic Dermatitis with a Focus on Pimecrolimus","volume":"35","author":"Luger","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Huang, I.-H., Chung, W.-H., Wu, P.-C., and Chen, C.-B. (2022). JAK-STAT Signaling Pathway in the Pathogenesis of Atopic Dermatitis: An Updated Review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1068260"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaci.2023.07.010","article-title":"The Role of Janus Kinase Signaling in the Pathology of Atopic Dermatitis","volume":"152","author":"Irvine","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The Role of JAK\/STAT Signaling Pathway and Its Inhibitors in Diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and Safety of Abrocitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis (JADE MONO-1): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/jdv.17813","article-title":"Patient-Reported Outcomes from the JADE COMPARE Randomized Phase 3 Study of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis","volume":"36","author":"Thyssen","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/bjd\/ljaf236","article-title":"Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adults with Moderate-to-Severe Atopic Dermatitis: Results of a Randomized Blinded Treat-to-Target Multicentre Phase IIIb\/IV Study (Flex Up)","volume":"193","author":"Gooderham","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/ddg.15908","article-title":"Upadacitinib Dose Adjustment in Moderate-to-severe Atopic Dermatitis: Insights from a Multicenter Real-world Study","volume":"23","author":"Dini","year":"2025","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ibba, L., Falcidia, C., Di Giulio, S., Bianco, M., Valenti, M., Facheris, P., Narcisi, A., Costanzo, A., and Gargiulo, L. (2025). Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14092953"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Iznardo, H., Ro\u00e9, E., Serra-Baldrich, E., and Puig, L. (2023). Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020385"},{"key":"ref_13","unstructured":"European Medicines Agency (2025, March 18). Cibinqo (Abrocitinib): Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/cibinqo-epar-medicine-overview_en.pdf."},{"key":"ref_14","unstructured":"European Medicines Agency (2025, March 18). Rinvoq (Upadacitinib): Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/epar\/rinvoq."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2605834","DOI":"10.1080\/09546634.2025.2605834","article-title":"Dose-Dependent Effectiveness and Patient-Reported Outcomes with JAK1 Inhibitors in Atopic Dermatitis: A 36-Week Multicenter Real-World Cohort","volume":"37","author":"Esen","year":"2026","journal-title":"J. Dermatol. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/jdv.20229","article-title":"Combining Treat-to-target Principles and Shared Decision-making: International Expert Consensus-based Recommendations with a Novel Concept for Minimal Disease Activity Criteria in Atopic Dermatitis","volume":"38","author":"Silverberg","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2024.01.004","article-title":"Clinical Outcomes and Management of JAK Inhibitor-Associated Acne in Patients with Moderate-to-Severe Atopic Dermatitis Undergoing Upadacitinib: A Multicenter Retrospective Study","volume":"90","author":"Avallone","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/ced\/llaf144","article-title":"Potential Role of Leptin in Janus Kinase 2 Inhibitor-Associated Weight Gain: A Monocentric Retrospective Study","volume":"50","author":"Ibba","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdin.2024.11.009","article-title":"Weight Gain Secondary to the Use of Oral Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis","volume":"19","author":"Xiong","year":"2025","journal-title":"JAAD Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40257-023-00798-0","article-title":"Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-World Setting: An Interim Analysis Through 48 Weeks of Observation","volume":"24","author":"Chiricozzi","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ibba, L., Gargiulo, L., Bianco, M., Di Giulio, S., Cascio Ingurgio, R., Alfano, A., Vignoli, C.A., Valenti, M., Facheris, P., and Perugini, C. (2026). JAK Inhibitors and Menstrual Cycle Alterations: Insights from a Case Series of 16 Female Patients. JDDG J. Dtsch. Dermatol. Ges.","DOI":"10.1111\/ddg.70173"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:14:48Z","timestamp":1781669688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061127"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061127","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}